Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting

Journal of Hematology & Oncology

Correspondence

Juanjuan Zhao¹  Quan Ren¹  Yongping Song¹  Xiangqian Guo²  Xinyuan Liu² 

[1] Department of Hematology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, China;Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Henan University, 475004, Kaifeng, Henan, China;

关键词: Multiple myeloma;    Bispecific antibody;    BCMA;    GPRC5D;    FcRH5;   

DOI  :  10.1186/s13045-023-01489-3

 received in 2023-06-20, accepted in 2023-07-26,  发布年份 2023

来源: Springer

【 摘 要 】

Several bispecific antibodies (bsAbs) targeting BCMA, GPRC5D, and FcRH5 are in clinical trials for heavily pretreated multiple myeloma (MM) patients. Teclistamab was approved for relapsed/refractory MM therapy in 2022, while elranatamab, linvoseltamab, F182112, talquetamab, and cevostamab are currently undergoing clinical trials. This study summarizes several latest reports on bsAbs for the treatment of MM from the ASCO 2023 Annual Meeting.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023